Department of Ophthalmology of Henan Provincial People's Hospital, Henan Eye Hospital, Henan Eye Institute, People's Hospital of Zhengzhou University, Zhengzhou, China.
Neonatal Intensive Care Unit of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Ophthalmologica. 2023;246(2):81-89. doi: 10.1159/000529393. Epub 2023 Jan 27.
The aim of this study was to compare the changes in serum concentrations of vascular endothelial growth factor (VEGF)-A and B after intravitreal injection of ranibizumab (IVR) or conbercept (IVC) for retinopathy of prematurity (ROP).
In this prospective study, infants with type 1 ROP in both eyes were recruited in our hospital from September 2021 to February 2022, randomly assigned to the ranibizumab and conbercept groups and administered IVR or IVC (0.25 mg/0.025 mL). Blood samples were collected before the operation and 1 and 4 weeks after the operation to measure the concentrations of serum VEGF-A and B.
A total of 20 ROP infants were randomly assigned to the ranibizumab (n = 10) and conbercept groups (n = 10). In the ranibizumab group, the serum VEGF-A concentrations before operation and 1 and 4 weeks after the operation were 73.55 ± 40.78, 11.47 ± 7.00, and 75.36 ± 30.87 pg/mL, respectively (p < 0.01). Least Significant Difference (LSD) pairwise comparison did not show any significant difference in the groups between 4 weeks postoperatively and preoperatively (p > 0.05). In the conbercept group, the serum VEGF-A concentrations before operation and 1 and 4 weeks after the operation were 86.69 ± 55.06, 14.68 ± 10.11, and 43.55 ± 57.92 pg/mL, respectively (p < 0.01). LSD comparison showed significant differences between 1 week and 4 weeks postoperatively and preoperatively (p < 0.05), but no significant differences were observed between 1 and 4 weeks postoperatively (p > 0.05). Regarding serum VEGF-B concentrations before the operation and 1 and 4 weeks after the operation, no significant differences were detected in the ranibizumab group (p > 0.05), but significant differences were observed in the conbercept group (7.26 ± 2.34, 3.09 ± 2.41, and 4.55 ± 3.37 ng/mL, respectively; p < 0.01). LSD showed significant differences between 1 or 4 weeks postoperatively and preoperatively (p < 0.05), but no significant difference was detected between 1 and 4 weeks postoperatively (p > 0.05).
Serum VEGF-A levels in infants with ROP were suppressed after IVR or IVC but returned to preoperative levels at 4 weeks after IVR and remained lower than the preoperative levels at 4 weeks after IVC. Serum VEGF-B was not affected by IVR but was suppressed by IVC for 4 weeks.
本研究旨在比较早产儿视网膜病变（ROP）患者玻璃体内注射雷珠单抗（IVR）或康柏西普（IVC）后血清血管内皮生长因子（VEGF）-A 和 B 浓度的变化。
本前瞻性研究纳入了 2021 年 9 月至 2022 年 2 月我院双眼 1 型 ROP 婴儿，随机分为雷珠单抗组和康柏西普组，并接受 IVR 或 IVC（0.25 mg/0.025 mL）治疗。于术前及术后 1 周、4 周采集血样，检测血清 VEGF-A 和 B 浓度。
20 例 ROP 婴儿被随机分配至雷珠单抗组（n=10）和康柏西普组（n=10）。雷珠单抗组术前及术后 1 周、4 周血清 VEGF-A 浓度分别为 73.55±40.78、11.47±7.00 和 75.36±30.87 pg/mL（p＜0.01）。最小显著差异（LSD）两两比较显示，术后 4 周与术前比较差异均无统计学意义（p＞0.05）。康柏西普组术前及术后 1 周、4 周血清 VEGF-A 浓度分别为 86.69±55.06、14.68±10.11 和 43.55±57.92 pg/mL（p＜0.01）。LSD 比较显示，术后 1 周与术前、术后 4 周与术前比较差异均有统计学意义（p＜0.05），但术后 1 周与术后 4 周比较差异无统计学意义（p＞0.05）。关于 VEGF-B 浓度，雷珠单抗组术前及术后 1 周、4 周差异均无统计学意义（p＞0.05），但康柏西普组差异有统计学意义（分别为 7.26±2.34、3.09±2.41 和 4.55±3.37 ng/mL，p＜0.01）。LSD 比较显示，术后 1 周或 4 周与术前比较差异均有统计学意义（p＜0.05），但术后 1 周与术后 4 周比较差异无统计学意义（p＞0.05）。
ROP 婴儿玻璃体内注射雷珠单抗或康柏西普后，血清 VEGF-A 水平受到抑制，但雷珠单抗组在 IVR 后 4 周恢复至术前水平，且仍低于 IVC 后 4 周的术前水平。IVR 不影响 VEGF-B，但可被 IVC 抑制 4 周。
